Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Lexicon Pharmaceuticals, Inc. LXRX
$2.86
-$0.26 (-8.92%)
На 18:00, 12 мая 2023
+249.65%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
601859350.00000000
-
week52high
3.79
-
week52low
1.31
-
Revenue
139000
-
P/E TTM
-6
-
Beta
1.32698900
-
EPS
-0.70000000
-
Last Dividend
0.00000000
-
Next Earnings Date
31 июл 2023 г. в 10:59
Описание компании
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | 12 авг 2022 г. | |
| Citigroup | Buy | Buy | 01 июл 2022 г. |
| Wedbush | Neutral | Outperform | 29 янв 2021 г. |
| JP Morgan | Neutral | Underweight | 29 янв 2021 г. |
| Citigroup | Buy | Neutral | 08 дек 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Artal International S.C.A. | A | 50859331 | 2426070 | 05 авг 2022 г. |
| Invus US Partners LLC | A | 5451204 | 147390 | 05 авг 2022 г. |
| DEBBANE RAYMOND | A | 5303814 | 982600 | 01 авг 2022 г. |
| Artal International S.C.A. | A | 48433261 | 16173800 | 01 авг 2022 г. |
| Invus US Partners LLC | A | 5303814 | 982600 | 01 авг 2022 г. |
| Swain Judith L | A | 9302 | 9302 | 21 мая 2022 г. |
| Swain Judith L | A | 14402 | 14402 | 21 мая 2022 г. |
| SOBECKI CHRISTOPHER J | A | 9302 | 9302 | 21 мая 2022 г. |
| SOBECKI CHRISTOPHER J | A | 14402 | 14402 | 21 мая 2022 г. |
| NIES ALAN S | A | 9302 | 9302 | 21 мая 2022 г. |
Новостная лента
Wall Street's Counting on an FDA Nod for This Growth Stock to Nearly Double, but Should You?
The Motley Fool
11 мая 2023 г. в 06:50
Lexicon's flagship medicine will go before regulators this month. There's a lot riding on getting an approval because it's running a bit low on cash.
Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023
GlobeNewsWire
28 апр 2023 г. в 16:00
THE WOODLANDS, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2023 financial results on Tuesday, May 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.
Should You Buy This Growth Stock Right Now Before It Potentially Doubles?
The Motley Fool
22 апр 2023 г. в 08:15
Lexicon is awaiting word from regulators about what could be its first product. Previously, regulators rejected its attempts to commercialize a similar program.
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023
GlobeNewsWire
21 апр 2023 г. в 09:00
THE WOODLANDS Texas, April 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc . (Nasdaq: LXRX), today announced that results from RELIEF-PHN-1, a Phase 2 double-blind, placebo-controlled trial of its investigational drug LX9211 for the treatment of postherpetic neuralgia, will be presented during the Emerging Science session at the AAN Annual Meeting, April 22-27, in Boston, MA: RELIEF-PHN-1: A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial of LX9211 in the Treatment of Postherpetic Neuralgia Pain - an oral presentation and poster (004), Monday April 24, 11:33-11:39 a.m.
Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023
GlobeNewsWire
28 февр 2023 г. в 17:00
THE WOODLANDS, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2022 financial results on Thursday, March 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.